Wegovy Pill Faces Safety Concerns as Telehealth Loopholes Emerge By Marcus Liu, Business Editor April 23, 2026 The introduction of an oral version of Wegovy has generated significant interest as a more convenient alternative to weekly injections for weight management. However, recent investigations reveal growing concerns about prescribing practices, particularly through telehealth providers, that may allow individuals who do not meet medical eligibility criteria to access the medication. Wegovy, whether in injectable or pill form, contains semaglutide and is approved for chronic weight management in adults with obesity or overweight conditions accompanied by weight-related health issues. Eligibility requires a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. Despite these safeguards, a recent investigation by Re: News found that some online general practitioners prescribed Wegovy without verifying patients’ weight or BMI. In one case, a reporter weighing 62kg—well below the BMI threshold for eligibility—received a prescription after a consultation lasting less than seven minutes. The investigation highlighted that certain telehealth services rely on patient-submitted images or self-reported measurements rather than in-person weigh-ins, creating opportunities for misuse. Experts warn that such loopholes pose serious risks, especially for individuals with eating disorders. Clinical psychologist Louise Adams noted during the investigation that a client with a BMI of 18 and restrictive anorexia was able to obtain Wegovy through an online provider. “That’s not medical care, that’s profiteering,” Adams stated, emphasizing that prescribing weight-loss medication to underweight individuals contradicts clinical guidelines and could exacerbate harmful behaviors. Medical professionals acknowledge the therapeutic value of Wegovy for appropriate patients. Dr. Nidhi Kansal, an internal medicine and obesity medicine specialist, confirmed that clinical trials present approximately 15% average weight loss over one year with consistent use. She also noted the pill version offers cost advantages, with a starting price of around $150 per month without insurance—lower than the weekly injectable form—and potential reductions to $25 monthly with coverage. However, Kansal stressed that the medication remains intended only for those meeting established medical criteria. “Body mass index over 30, or body mass index over 27, plus a weight-related health issue,” she said, citing examples such as pre-diabetes, hypertension, or fatty liver disease. The convenience of the oral formulation has driven rapid adoption, with nearly 200,000 people reportedly using the Wegovy pill within weeks of its December 2025 launch. Yet this popularity has intensified scrutiny over whether adequate safeguards exist to prevent inappropriate prescribing, especially in virtual care settings where physical assessments are limited. As telehealth continues to expand access to obesity treatments, regulators and healthcare providers face mounting pressure to strengthen verification processes. Ensuring that medications like Wegovy reach only those who medically require them remains critical to maintaining both patient safety and public trust in emerging weight-loss therapies.
24